Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships (Q35827780)

10 August 2017

Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships (English)

1 reference

10 August 2017

David Henry

3

0 references

author name string

Patricia McGettigan

series ordinal

1

1 reference

10 August 2017

Pearline Han

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

62

1 reference

10 August 2017

3

1 reference

10 August 2017

358-365

1 reference

Phytochemistry: ibuprofen-like activity in extra-virgin olive oil

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

11 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885143

Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors

24 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02660.X

10.1111/J.1365-2125.2006.02660.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

16934052

1 reference